Viral and Non-Viral Vector Manufacturing Market Future Scope and Latest Trends Analysis Report

Viral and Non-Viral Vector Manufacturing Market worth $23.49 billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Viral and Non-Viral Vector Manufacturing Market (Vector Type (Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, Other Viral Vector), Non-Viral Vectors, (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Other Non-Viral Vector (Peptide-Based And Hybrid/Combination))), Diseases (Cancer, Genetic Disorder, And Infectious Diseases), Application (Gene Therapy (Viral Vector, Non-Viral Vector), Vaccinology (Viral Vector, Non-Viral Vector), Cell Therapy (Viral Vector, Non-Viral Vector) And Other Applications (Viral Vector, Non-Viral Vector))) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get Free Sample Copy of Report : https://www.insightaceanalytic.com/request-sample/1263
According to the most recent research by InsightAce Analytic, the global viral and non-viral vector manufacturing market was valued at $5.01 billion in 2021 and is projected to reach $23.49 billion by 2030, expanding at a CAGR of 19.04% from 2022 to 2030.
Using vectors, advanced gene and cell therapies have significantly impacted the medical field. Numerous chronic diseases and neurological disorders are amenable to treatment with genetically modified therapies. Gene therapy has the potential to treat and manage a variety of conditions effectively. Viral vectors are the most frequently used agents in gene therapy due to their exceptional capacity to convey copies of therapeutic genes to host cells. Adeno-associated vectors (AAV) are the most promising of this class of vectors due to their transient nature, capacity to transduce both dividing and non-dividing cells, and low immunogenicity. Several clinical studies demonstrating the efficacy of vector-based therapies have increased the importance of developing viral and non-viral vectors to address unmet medical requirements.
Multiple factors, such as the rising prevalence of fatal diseases and the increasing use of next-generation technologies in developing innovative drugs, are the primary drivers of market expansion. In the coming years, the growing prevalence of vector-based gene and cell therapies, the high demand for customized medications, the rising R&D expenditures for vector-based therapeutic breakthroughs, and the well-established healthcare infrastructures are expected to drive significant market expansion. Increasing occurrences of chronic and infectious diseases increase the demand for therapies requiring genetic modification, thereby presenting numerous opportunities for the viral and non-viral vector manufacturing market to expand.
In contrast, the high cost of vector production, the complications associated with the large-scale production of viral and non-viral vectors, and the low transfection efficiency may impede the market's growth in the coming years.
In the coming years (2020-2030), North America is anticipated to lead the global viral and non-viral vector manufacturing market due to the increasing R&D activities in vector-based therapy innovations and the accelerated adoption of advanced therapy techniques.
Key market players operating in the viral and non-viral vector manufacturing market include Boehringer Ingelheim (Germany), Catalent, Inc. (US), FUJIFILM Holdings Corporation(Japan), Danaher Corporation (US), Genscript Biotech Corporation (US), Lonza Group AG (Switzerland), Merck KGaA Inc. (Germany), Oxford Biomedica plc (UK), Sartorius AG (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (US), Wuxi AppTec (China), Acuitas Therapeutics (Canada), Evonik Industries AG (Germany), Exelead, Inc. (US), Entos Pharmaceuticals (Canada), Genevant Sciences GmbH (Switzerland), T&T Scientific Corporation (US), Moderna, Inc. (US), CureVac N.V. (Germany), Cognate BioServices Inc. (Cobra Biologics), Genezen Laboratories, Yposkesi, Waisman Biomanufacturing, Advanced Bioscience Laboratories, Inc. (Abl Inc.), Novasep Holding S.A.S., Batavia Biosciences B.V., Biovion Oy, Sirion Biotech Gmbh., Virovek Incorporation, Biontech Imfs Gmbh, Vivebiotech S.L., Creative Biogene, Uniqure NV, Cell and Gene Therapy Catapult, Cevec. Pharmaceuticals Gmbh among others.
Key developments in the market:
• In May 2022, Catalent launched its latest UpTempo VirtuosoTM platform method for developing and CGMP production of adeno-associated viral (AAV) vectors. The UpTempo Virtuoso platform standardizes and streamlines several time-consuming procedures in AAV manufacture to drastically minimize the time from gene to clinic and enable quick clinical assessment of the first patient.
• In December 2021, GenScript ProBio (US) opened China's most prominent commercial GMP plasmid manufacturing facility. The 6,400-square-meter manufacturing plant enables the company to offer global customers a one-stop service for plasmids - from the preclinical study (IIT) to the investigational new drug (IND) filing to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.
• In December 2021, Oxford Biomedica plc (UK) extended a commercial supply agreement with Novartis to manufacture lentiviral vectors for several Novartis CAR-T products.
• In October 2021, Matica Biotechnology, Inc, a (CDMO) specializing in the clinical and commercial production of cell and gene therapies, announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on several studies to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large-scale vector production.
• In April 2021, Oxford Biomedica plc (UK) signed a new three-year Development & Supply Agreement ("DSA") with Boehringer Ingelheim to manufacture & supply various types of the viral vector.
• In Jan 2021, Thermo Fisher Scientific Inc. and Groupe Novasep SAS (Novasep) announced that Thermo Fisher acquired Novasep's viral vector manufacturing company in Belgium, Henogen S.A. The viral vector manufacturing division of Novasep offers contract manufacturing services for vaccines and medicines to biotechnology and major biopharma clients.
Enquiry Before Buying @ https://www.insightaceanalytic.com/enquiry-before-buying/1263
Market Segments
Global Viral and Non-Viral Vector Manufacturing Market, by Vector Type, 2020-2030 (Value US$ Mn)
• Viral Vector
o Adenoviral Vector
o Retroviral Vector
o Adeno-Associated Viral Vector
o Lentiviral Vector
o Vaccinia Viral Vector
o Other Viral Vector
• Non-Viral Vectors
o Plasmid DNA
o Lipid-Based Non-Viral Vector
o Polymer-Based Non-Viral Vector
o Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)
Global Viral and Non-Viral Vector Manufacturing Market, by Disease, 2020-2030 (Value US$ Mn)
• Cancer
• Genetic Disease
• Infectious Disease
• Cardiovascular Disease
• Other Diseases
Global Viral and Non-Viral Vector Manufacturing Market, by Application, 2020-2030 (Value US$ Mn)
• Gene Therapy
o Viral Vector
o Non-Viral Vector
• Vaccinology
o Viral Vector
o Non-Viral Vector
• Cell Therapy
o Viral Vector
o Non-Viral Vector
• Other Applications
o Viral Vector
o Non-Viral Vector
Global Viral and Non-Viral Vector Manufacturing Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
For Customised Information @ https://www.insightaceanalytic.com/customisation/1263
Other Related Reports Published by InsightAce Analytic:
Global Gene Therapy for Blood Disorders Market
Global Gene Therapy For Retinal Diseases Market
Global Cell and Gene Therapy Drug Delivery Devices Market
Global iPSCs Manufacturing Services Market
Global mRNA Synthesis and Manufacturing Services Market
Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global viral and non-viral vector manufacturing market
 To receive an industry overview and future trends of the viral and non-viral vector manufacturing market
 To analyze the viral and non-viral vector manufacturing market drivers and challenges
 To get information on the viral and non-viral vector manufacturing market size (Value US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the viral and non-viral vector

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.